Literature DB >> 9781472

Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis.

Y Barak1, M Swartz, E Shamir, D Stein, A Weizman.   

Abstract

Tardive dyskinesia is an involuntary movement disorder developing following treatment with neuroleptics. As many as 50% of chronic psychotic patients develop this disabling condition. No treatment has been found effective for tardive dyskinesia. This study was undertaken to meta-analyze the effects of vitamin E (alpha-tocopherol) reported in the last decade. All studies published since 1987, focusing on vitamin E and tardive dyskinesia are reviewed. Double-blind studies are analyzed using measures of effect and variance as described by secondary analysis of magnitude of effects in pooled data. A total of 223 patients received vitamin E treatment (400-1600 IU/day) for tardive dyskinesia, in 12 studies. A significant subgroup (28.3%) showed a modest improvement. Vitamin E was well tolerated, and only rarely did side effects occur-of no clinical significance. Vitamin E is a safe, well-tolerated compound that may provide some beneficial effects in patients suffering from neuroleptic-induced tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781472     DOI: 10.1023/a:1022349920283

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  10 in total

Review 1.  Oxidative mechanisms and tardive dyskinesia.

Authors:  James B Lohr; Ronald Kuczenski; Alexander B Niculescu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

Review 3.  Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Karen Berman; Henry Brodaty
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  Reporting of systematic reviews of micronutrients and health: a critical appraisal.

Authors:  Mei Chung; Ethan M Balk; Stanley Ip; Gowri Raman; Winifred W Yu; Thomas A Trikalinos; Alice H Lichtenstein; Elizabeth A Yetley; Joseph Lau
Journal:  Am J Clin Nutr       Date:  2009-02-25       Impact factor: 7.045

5.  Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.

Authors:  M Lazzarini; C Salum; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 6.  Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.

Authors:  M R Caligiuri; D V Jeste; J P Lacro
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 7.  Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.

Authors:  Joseph M Pierre
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 8.  Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting.

Authors:  N Zisapel
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

9.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

10.  Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.

Authors:  S R Thaakur; B Jyothi
Journal:  J Neural Transm (Vienna)       Date:  2007-05-26       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.